Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
23.38
-0.36 (-1.52%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $9.04M in the quarter ending May 31, 2026, a decrease of -79.47%. This brings the company's revenue in the last twelve months to $36.77M, down -58.40% year-over-year. In the fiscal year ending November 30, 2025, Nurix Therapeutics had annual revenue of $83.98M with 53.95% growth.
Revenue (ttm)
$36.77M
Revenue Growth
-58.40%
P/S Ratio
66.00
Revenue / Employee
$115,981
Employees
317
Market Cap
2.43B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2025 | 83.98M | 29.43M | 53.95% |
| Nov 30, 2024 | 54.55M | -22.44M | -29.15% |
| Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
| Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
| Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
| Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
| Nov 30, 2019 | 31.12M | -6.33M | -16.91% |
| Nov 30, 2018 | 37.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 535.08M |
| Vericel | 292.09M |
| Beam Therapeutics | 164.01M |
| Nektar Therapeutics | 55.63M |
| Immunome | 4.02M |
NRIX News
- 4 days ago - Nurix Therapeutics price target raised to $31 from $23 at UBS - TheFly
- 4 days ago - Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology - GlobeNewsWire
- 13 days ago - Nurix Therapeutics price target raised to $34 from $30 at Mizuho - TheFly
- 16 days ago - Nurix Therapeutics price target raised to $34 from $32 at Truist - TheFly
- 16 days ago - Nurix Therapeutics price target raised to $33 from $30 at RBC Capital - TheFly
- 16 days ago - Nurix Therapeutics price target raised to $40 from $34 at Stifel - TheFly
- 16 days ago - Nurix Therapeutics price target raised to $34 from $32 at H.C. Wainwright - TheFly
- 16 days ago - Nurix Therapeutics reports Q2 EPS (81c), consensus (72c) - TheFly